Related Blog Posts from the Wikinvest Wire

Edwards Lifesciences (EW)   Subscribe to Edwards Lifesciences (EW) content from the Wikinvest Wire
 » Back to Edwards Lifesci… (NYSE:EW) Stock Page

  

1/16/14Medtronic Inc. (NYSE:MDT) | Edwards Lifesciences to likely get compensation from Medtronic, says ... (Jutia Group)

[theflyonthewall.com] - Wells Fargo believes that Medtronic (MDT) will have to pay either a royalty or lost profits to Edwards Lifesciences (EW) after a jury ruled that Medtronic had infringed on an Edwards Lifesciences patent. ... Read more on this. Medtronic, Inc. (MDT), valued at $59.32B, began trading this morning at $59.38. [...]

9/7/13(EW) Edwards Lifesciences Sees Promising Data on Sapien XT (Stock Blog Hub)

World’s leading provider of heart valves and hemodynamic monitoring Edwards Lifesciences Corporation (EW) disclosed positive one-year data on Edwards Sapien XT trans-catheter aortic heart valve from the post-approval study in Europe. The company presented the data from the SOURCE XT Registry at the EuroPCR 2013 in Paris. The SOURCE XT Registry is evaluating the performance of [...]

6/16/12(EW) Company News for June 15, 2012 – Corporate Summary (Stock Blog Hub)

•    Edwards Lifesciences Corp. (NYSE:EW) gained 7% after the FDA  approved the company’s Sapien heart valve as for a wider section of patients •    International Game Technology (NYSE:IGT) rose 14.4% after it announced it would buy back $1 billion of its common stock. The company has concluded an agreement with Goldman Sachs Group, Inc. (NYSE:GS) for [...]

6/14/12Edwards Lifesciences Corp. (EW) Has Climbed To A New High On FDA Recommendation (Penny Stock DD)

Edwards Lifesciences Corp. (EW: News ) announced after the bell Wednesday that an FDA Advisory Panel voted in favor of recommending approval of the Edwards SAPIEN transcatheter heart valve via transfemoral and transapical delivery, for the treatment of high-risk patients with severe, symptomatic aortic stenosis. Edwards Lifesciences has spiked to the upside in early trade and is [...]

2/2/12New EW Silver Discovery By Alf Fields (Gold Stocks Today)

Dear Friends, Since my apprenticeship with Bert Seligman in the 1950s, I have felt that no matter what tool a person uses in the market, the consistently successful have a mercantile sense for the subject of their attention and it is that mer...

1/11/12New Year, New High Hopes for Stocks (Phil’s Stock World)

Elliott Wavers believe "Stocks don't follow the economy. It's the other way around: The economy follows stocks." I highly doubt that. There may be some correlations, but it's not a cause and effect relationship either way. Nevertheless, it's interesting to see what EW Int. is writing about (whether you agree with their premise or not) [...]

11/10/11(EW) Edwards Lifesciences Earns FDA OK on Trial Enrollment (Stock Blog Hub)

Recently, Edwards Lifesciences Corporation (EW) received conditional approval from the US Food and Drug Administration for enrollment of a certain group of patients in the PARTNER II trial. The trial is studying the company’s next-generation Sapien XT transcatheter heart valve (THV). Under the new cohort (PARTNER II Cohort A) of the trial, patients (up to 2,000) [...]

10/31/11(EW) Edwards Lifesciences 2011 Fourth Quarter Earnings Scorecard (Stock Blog Hub)

The announcement of Edwards Lifesciences’ (EW) third quarter fiscal 2011 results as on October 19, 2011, has led analysts to revise their estimates lower for the fourth quarter and fiscal 2011. Third Quarter Highlights Edwards reported an adjusted EPS of 38 cents in the third quarter of fiscal 2011, a penny below the Zacks Consensus Estimate, and missing [...]

10/18/11(EW) Edwards Lifesciences Corporation Earnings Preview (Stock Blog Hub)

Edwards Lifesciences Corporation (EW) is scheduled to release its third quarter fiscal 2011 results on Wednesday, October 19, 2011 after the market closes. The company is expected to earn 39 cents per share during the quarter on $405 million in revenues, according to the Zacks Consensus Estimate. The consensus estimate is lower that the year-ago quarter’s [...]

10/6/11(EW) Edwards Lifesciences Announces Share Buyback (Stock Blog Hub)

Edwards Lifesciences Corporation (EW) recently announced a new share repurchase program worth $500 million. At the end of the second quarter of fiscal 2011, the company was left with $240 million of authorization. Edwards expects to repurchase approximately $100 million worth of additional shares during the third quarter of the current fiscal. Edwards exited the second [...]

10/2/11(EW) Edwards Lifesciences Sapien Under Centers for Medicare & Medicaid Services NCA (Stock Blog Hub)

Edwards Lifesciences (EW) received a major setback as the Centers for Medicare & Medicaid Services (CMS) decided to initiate a National Coverage Analysis (NCA) of transcatheter aortic valve replacement (TAVR). As a result, the stock price of the company closed 6.58% lower on Thursday. According to the agency, it received a formal national coverage determination [...]

6/18/11Elliott Wave (EW) works when it's objective, so trade these levels: Tony Caldaro's OEW weekend up... (CHARTLINES (tm))

Most Elliott Wave (EW) analysts fail because they lose objectivity. But the theory and method remain valuable, so we feature Tony Caldaro who remains objective; and promptly reevaluates if his levels are violated and alternatives become valid. Here's his weekend update of his Objective Elliott Wave analyses of world financial markets, commodities, bonds, currencies, and economic indicators; in this "the ELLIOTT WAVE lives on" update (thanks again Tony!). Keep up with his posts and, via his...

4/9/11(EW) Edwards Lifesciences’ Sapien Transcatheter Heart Valve on Way to Success (Stock Blog Hub)

Recently, Edwards Lifesciences (EW) presented positive data for its Cohort A of the PARTNER trial at the American College of Cardiology annual conference in New Orleans. The PARTNER trial is evaluating Edwards’ Sapien transcatheter heart valve (THV) in both operable (Cohort A) and inoperable (Cohort B) patients with severe aortic stenosis. It was observed that [...]

4/4/11(EW) Edwards Lifesciences to Present PARTNER Data (Stock Blog Hub)

Edwards Lifesciences (EW), will present data from the Cohort A of the PARTNER trial at the American College of Cardiology annual conference in New Orleans in early April. The PARTNER trial is evaluating Edwards’ Sapien transcatheter heart valve (THV) in both operable (Cohort A) and inoperable (Cohort B) patients with severe aortic stenosis. Patients (699) under Cohort [...]

2/19/11Edwards Lifesciences: A Heart-Felt Buy (Penny Stock DD)

"Edwards Lifesciences (EW) is a potential winner; based in Irvine, California, Edwards makes and sells replacement valves for advanced heart disease," says growth stock specialist Alexander Green. The editor of The Oxford Club explains, "Edwards has a breakthrough product called SAPIEN, a transcatheter valve that allows doctors to replace a heart valve [...]

12/8/10Rydex Launches Five Equal Weight ETFs (EWRI, EWRS, EWRM, EWEF, EWEM) (Wall Street Sector Selector)

Rydex today unveiled five new equal weight (EW) ETFs, which are ETFs that weight investment holdings equally across either index constituents and/or market segments.  A pioneer in the EW ETF space, the firm’s flagship ETF, Rydex S&P Equal Weight ETF (RSP), was launched in 2003 and has(...)Read the rest of Rydex Launches Five Equal Weight ETFs [...]

10/26/10Goldman Sachs Reiterates Neutral Rating on Edwards Lifesciences (EW) (Benzinga)

Goldman Sachs is out with a research report this morning, where it reiterates its Neutral rating on Edwards Lifesciences Corp. (NYSE: EW); it has a $76.00 price target on the stock. The GS analysts cited the company's recently announced quarterly earnings report, which misses the Street's estimates due to lower segment sales across all businesses. The analysts said that they are maintaining the Neutral rating given what they continue to view as balanced risk/reward at current levels....

10/25/10Edwards Lifesciences Beats on EPS; Revenues Light (EW) (Benzinga)

Edwards Lifesciences Corp. (NYSE: EW) reports Q3 earnings of $0.43 versus consensus of $0.42. Edwards Lifesciences Corp. reports revenues of $348.9 million versus consensus of $353.32 million. "Continued demand for our innovative new products again drove double-digit underlying sales growth this quarter, which gives us confidence to raise our earnings outlook for this year," said Michael A. Mussallem, Edwards Lifesciences' chairman and CEO. "Based on improved foreign exchange rates and...

10/21/10Top 4 Mid-Cap Stocks In The Medical Appliances & Equipment Industry With The Highest Cash (VAR, H... (Benzinga)

Below are the top mid-cap medical appliances & equipment stocks on the NYSE and the NASDAQ in terms of cash. Varian Medical Systems Inc (NYSE: VAR) had $587.61 million in total cash and $23.46 million in total debt for the latest quarter. Hologic Inc (NASDAQ: HOLX) had $491.37 million in total cash for the latest quarter. HOLX's total debt stood at $1.43 billion in the same period. Smith & Nephew SNATS Inc (NYSE: SNN) had $360.00 million in total cash for the latest quarter. Meanwhile,...

9/30/10Where we are (All Allan)

SPX Hourly with Trend Model and EW count From the late August low (five waves down) the SPX has risen in five waves up.  Wave five up could extend, but as long as you can count five waves up, it could reverse down at any time in either an ABC correction or the beginning of a new five waves down.  If SPX closes lower on the day, its likely that the rally from August is over. I have no idea why the first chart doesn't expand with a click.  

9/23/10Edwards Lifesciences Is Skyrocketing (Benzinga)

Shares of Edwards Lifesciences Corp. (NYSE: EW) are skyrocketing today on news that the company had favorable data for its "Sapiens" heart valve. The FDA subsequently approved a follow on trial, which is being seen as a positive for the products approval. The company also received a favorable write up in the New England Journal of Medicine. Edwards also received two upgrades in price targets this morning, from Deutsche Bank and Piper Jaffray. Shares are currently up $7.47 or 12.51% to...

9/23/10Benzinga's Top Upgrades (PT, EW, ENDP, AMTD) (Benzinga)

Portugal Telecom SGPS SA (NYSE: PT) was upgraded by Nomura from “reduce” to "neutral." PT's shares closed at $12.87 yesterday. Portugal Telecom's quarterly earnings gained 82.50% y/y. Piper Jaffray upgraded Edwards Lifesciences Corp (NYSE: EW) from "neutral" to "overweight." EW's shares closed at $59.70 yesterday. Edwards' earnings have risen by 169.57% in the past five years. Endo Pharmaceuticals (NASDAQ: ENDP) was upgraded by UBS from "neutral" to "buy." ENDP's shares closed at...

9/23/10PARTNER B Does Not Disappoint, According to Citi (Benzinga)

Citigroup writes for Edwards Lifescinces (NYSE: EW) that the "PARTNER Cohort B trial data forms the basis for the company's PMA filing and we believe SAPIEN will be approved by the FDA in 2H11. Now that the primary endpoint hurdles have been met, we believe the investment debate will shift to market adoption with a focus on support, training and delivery. In addition, we believe new embolic protection devices will also receive attention in order to address vascular and stroke-related...

9/23/10Edwards Receives Approval to Begin U.S. Clinical Trial (EW) (Benzinga)

Edwards Lifesciences Corporation (NYSE: EW) earlier today announced that the U.S. Food and Drug Administration (FDA) conditionally approved the first of two planned cohorts of the randomized, controlled The PARTNER II Trial. Building upon the learnings of the world's first randomized transcatheter heart valve trial -- Edwards' The PARTNER Trial -- the first cohort of The PARTNER II Trial will study the next-generation Edwards SAPIEN XT transcatheter heart valve. This trial includes the...

9/23/10Piper Jaffray Upgrades Edwards Lifesciences (Benzinga)

Piper Jaffray is upgrading shares of Edwards Lifesciences (NYSE: EW) to Overweight from Neutral, and raising its price target to $77 from $53 on strong results from the PARTNER trial. In the research note, Piper Jaffray writes, "We are upgrading Edwards Lifesciences from Neutral to Overweight based on the robust results from the PARTNER trial which were published last night in the New England Journal of Medicine. The study showed that at one year, patient treated with the Sapien valve...

9/23/10Deutsche Bank Raising Price Target On Edwards Lifesciences (Benzinga)

Deutsche Bank is raising its price target on Edwards Lifesciences Corp (NYSE: EW) to $68 after the company announced positive Cohort B data. This makes FDA approval more likely. It has an Hold rating on shares. In the research note, Deutsche Bank writes, "The Cohort B data were positive and supportive of an ultimate FDA approval. In our view, the market view was for the trial to be good enough for approval, though it was better than likely expected as it hit superiority. At this time, we...

9/23/10New PT For Edwards Lifesciences (Benzinga)

JP Morgan writes for Edwards Lifesciences (NYSE: EW) "[O]ur new $61 [up from $53] Dec 2010 price target is based on our DCF valuation and corresponds to a 29x multiple on our 2011 earnings estimate. This represents a significant premium to the current SMID-cap Medtech average NTM P/E of 15.4x, which we believe fully captures the long-term potential of the company's transcatheter valve program." JP Morgan maintains its Underweight rating for Edwards Lifesciences, which closed yesterday at...

9/21/10Big Gainers On The Day (EW, JOBS, EBIX) (Benzinga)

Despite the indexes coming back to the flat line today after the Federal Reserve released its interest rate statement, there are a few stocks moving sharply higher today. Shares of Ebix Inc (NASDAQ: EBIX) are up sharply today on strong volume. Ebix, Inc. provides software and e-commerce solutions to the insurance industry across the globe. Shares of EBIX are up 3.1% or 64 cents to $21.28. Volume is exceptionally strong today, having traded more than 1 million shares. The average...

5/25/10SPX - dominant trend (All Allan)

Following up on my post from last night, here is the current SPX Daily chart with a potential EW count that suggests an initial target of 925-975 for this move: SPX Daily Trend Model I still find it fascinating how prices tend to approach the trend line on retracements, then fall short and resume the dominant trend.  Look at the most recent set of blue candles, five "up" candles that retraced to the vicinity of the trend line around May 10-14, then  resumed the downtrend.  This...

5/19/10April Showers ---> May Flowers (All Allan)

Three prominent Shorts from April that were discussed here in real time. X Daily Trend Model GOOG Daily Trend Model GS Daily Trend Model The chart titles link to the April, 2010 blogs that first posted the Sell Signals.  The EW counts included in these charts were not known at the time of the signals, but are known now, in retrospect. Not all Trend Model signals result in Wave 3 downtrends, but when they do, they make up for any prior whipsaws and then some.

5/14/10DJIA - Weekly Trend Model (All Allan)

DJIA Weekly Trend Model w/EW The Weekly DJIA highlights just how far this next wave down has to go, if it indeed is a 5th wave to complete the suggested EW pattern.  Robert Prechter would suggest hat this EW count is wrong, that in fact the DJIA is entering into a Wave 3 down, not a Wave 5 down.  So of these two counts, the one above is suggesting only a drop to below 7,000 to complete five waves, where Prechter is suggesting a drop much, much lower, below 1,000 before we start looking...

5/13/10Would you buy this stock? (All Allan)

VXX Daily Trend Model 2.0 with EW VXX Daily Trend Model 4.0 w/EW Would you buy this stock?   If yes, consider the implications.  As VXX rises, the general market falls.  Both of these charts are suggesting that VXX is in the early stages of a new uptrend. Conversely, the same analysis suggests that the stock market is in the early stages of a downtrend.   In the first chart, using my default trend settings, there is not much room for the VXX to fall without...

4/19/10Chart updates (All Allan)

I sent an interim to my email list this morning, updating the price threshold for SDS flipping Long in its Daily Trend Model.  SDS is moderately leveraged and represents a good proxy for any intermediate market downturn.  DJIA Daily Trends with EW analysis Once again we can see a divergence between last week's highs and the Elliott Oscillator in the bottom panel.  A break down here will represent a Mechanical Sell Signal, although for our purposes, a break of the trend line will...

4/11/10The Wheel (All Allan)

Below is my QQQQ chart, including the Daily Trend Model, an EW count, Auto-Trend Channels and the Elliott Oscillator. Since the mid-February LONG signal, the index is up about 10%.  Prices have been contained in a well defined trend channel, all the time safely above the Daily Trend Line (navy).  On the bottom oscillator, the recent new highs in price are not being confirmed by new highs in the oscillator.  This suggests that the proposed wave count on the screen is correct and that...

3/23/10ChartsEdge Pattern Recognition map for 3/23 (CHARTLINES (tm))

Will today provide the "low of the week" for a swing buy into Friday? That's what the ChartsEdge weekly forecast suggested, for equities as well as gold (maybe oil too). Nothing is ever guaranteed of course. In fact, Monday's morning low may have been it, with today giving a higher low, but if it's an EW flat pattern then today's low can be either higher or lower. That's just my own thought; and of course Tony Caldaro with his OEW, and separately Andre Gratian, and Terry Laundry, are...

3/8/10On Elliott Wave, Implusive Trading, and Trading Plans (The Essentials of Trading)

I've had a few questions come in over the last several days which don't really require a full post to answer, so I'm going to hit them together. Here's the first: If you love helping people get the most out of their trading, I would like to ask you where I can find good Elliot Waves [...]

3/6/10Double Top? (All Allan)

The Value Line index is the one major equity index that doesn't look so much like a big picture counter-trend rally correcting a previous first wave down.  Instead, it looks like a massive double top. Value Line Monthly Value Line Weekly VLE with EW count showing non-confirmation  in Elliott Oscillator Let's add the VLE Daily Trend Model VLE 240m Trend Model w/Vortex Indicator Do I really expect to catch the exact top of a massive...

12/12/09New horizons (All Allan)

I started out about three hours ago, intending to update the TZA system stats and tease everyone with my new scalping system which is holding up with 85% winning trades, now going back 5.5 years in my back testing model. Or maybe just a graphic review of EW counts and analysis which paint the same portrait of a market hovering on fumes, about to go into free fall. I also wanted to update NNVC, which I can tell you already, is my stock of year for 2010.  This could be a weekend blog in and...

12/4/09DJIA Monthly EW Analysis (All Allan)

There is a lot of forecasting going on in this monthly chart of the Dow Jones Industrial Average, all courtesy of the internal algorithms of Advanced GET software. In summary, the EW pattern is of an unfinished 5 waves down from the late 2007 highs.  The blue shaded ellipse is suggesting that current price levels are the likely end of the Wave 4 advance from March, 2009.  The horizontal blue-shaded support levels are suggesting a Wave 5 forecast low at 6000 circa September,...

8/23/09Hanging with the A (All Allan)

I think most of you get this, but from a few Comments , some of which never saw the light of day here, there remains some confusion about my charts and analysis. The above chart is a Weekly SPX with two analysis methodologies applied. First, an internal Elliott Wave count which is suggesting an uncompleted cycle down, i.e. a Wave 5 is still to come to new lows. Also included is an ATR_TrailingStop indicator ( LONG/EXIT-SHORT ), that signals price bias without regard to the EW ...

7/16/09ChartsEdge (U.S. equities) map for 7/16 (UnBiasedTrading (TM))

Market Map for Jul16 Posted: July 16th, 2009 Author: Mike Korell Filed under: One-Day Market Map Comments to ChartsEdge » ============= Thanks once again, Mike and ChartsEdge! And thanks to Andre Gratian, who exchanged notes with me yesterday, as I was saying "congrats" to him for calling the rise through yesterday! So, folks, as I stayed up too late last night noodling around Elliott Wave alternatives - and I should know better than that, as EW can lend itself to different...

7/7/09Fun with Elliott Wave - short term (Gold Versus Paper)

src="http://pagead2.googlesyndication.com/pagead/show_ads.js">I am not an expert at this Elliott Wave (EW) stuff and it can sure get you into trouble if you use it as a stand-alone tool, but it can also give some stunningly accurate road maps

5/27/09Taking every sell (All Allan)

Based on the Weekly SPX chart that I have been posting for three months now, we are in a window from which a major turn down could assert itself. Therefore I am taking every Sell on the 120 Minute Blue Wave chart, especially where EW ( Elliott Wave ) or FBS ( False Bar Stochastic ) are confirming. Below are three tradables with prices presented as a line so its easier to see the uncanny accuracy of BW trades. Note also the EW counts and FBS confirmations. FAZ...

5/1/09Can you hear me now? (All Allan)

A couple of interesting Big Picture charts from Henry Blodget of Clusterstock. This pretty much sums up where we are, where we have come from and maybe, where we are going. To simplify, these charts suggest that another 50% or more down is ahead for the markets, which is pretty much in line with the EW forecast from my weekly charts. As for current market sentiment, Blodget observes that, "Market punditry is a lagging indicator, not a leading one. Pundits are excellent at describing...

4/24/09EW bearish wedge formation in SPX and likely target (UnBiasedTrading (TM))

The bearish Elliott Wave formation in the SPX is looking like it already finished its peak last Friday (a week ago). With the low of Monday/Tuesday earlier this week, being the "A" wave of the first move down from that; and today's high being the "B" wave pullback up. Given this construct, then we may expect wave "C" down traveling to the area of 780 SPX. This is because 780 is the level from which the diagonal started, hence the classic minimum target of a diagonal wedge in Elliott Wave...

3/23/09To the point (All Allan)

Some personal matters necessitate an abbreviated post tonight. In fact the daily postings are in jeopardy for various and sundry reasons, including but not limited to taxes. So quickly, here is how I see things. Above is today's BW Trend 30 minute chart. That first long blue bar was pre-market, but there was immediate follow through so the system was long all day, into the close. Above is the Weekly EW chart. Note that today's bar has broken out of the long term regression channel...

3/15/09Beware Caesar, The Ides of March (All Allan)

Lest we not forget, the major trend is down. Below are Weekly charts that define the primary trend of the market: The pattern that I posted Friday afternoon still stands. Below is the EW 120 minute chart showing the familiar counter-trend rise against a longer term downtrend: As one of you pointed out, that False Bar Stochastic is flattening out suggesting the possibility of this small uptrend continuing. But the position of the channels don't allow for much upside before something...

3/11/09Sometimes, less is best (All Allan)

Exactly when is less best? When Allan doesn't have time to post, but finds time anyway, albeit not a lot. So let's get to it: This is what we are up against. The above double 120 minute charts make the case for further advance as well as imminent decline. Starting the EW chart on the right we see an unfinished five wave advance, but accompanied by a False Bar Stochastic Sell in the making: While the Blue Wave chart on the left shows an uptrend, but one that is losing momentum and...

2/24/09Alternate Elliott Wave views of the S&P 500 near-term (UnBiasedTrading (TM))

There are always a few alternative possibilities for the near-term Elliott Wave in a chart, so let's look at the most prominent that I know of. First, there's Tony Caldaro with his Objective Elliott Wave methods. He recently revised his S&P 500 count to correspond with his Dow Jones Industrial Average count, and here it is: Clearly, the count points yet lower, because after a 4th wave there is a 5th wave projected, in this case pointing down. So this count tells us that, after a 4th wave...

2/7/09On being prepared (All Allan)

Before I address what lays ahead for the market, it has come to my attention that some of you just don't get it: Anonymous said... Hah! You're EW theory just got fu*ked. See??? News trumps all!!! First, profanity is out of place on my blog and I will not tolerate it. If I have to go back to moderating comments, so be it. Second, one rally is inconsequential to the Elliott Wave Principle and even less meaningful to my analysis. Let's review. Here in relevant part is my analysis from last...


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki